Cargando…
The use of SGLT2 inhibitors in achieving glycaemic control in maturity-onset diabetes of the young type 3
SUMMARY: Maturity-onset diabetes of the young type 3 (MODY3) accounts for approximately 50% of cases of MODY. First-line treatment with sulfonylureas has been well established for individuals with MODY3. In contrast, the use of sodium-glucose co-transporter 2 (SGLT2) inhibitors in the treatment of i...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Bioscientifica Ltd
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8686174/ https://www.ncbi.nlm.nih.gov/pubmed/34866061 http://dx.doi.org/10.1530/EDM-21-0102 |